Neurogene Inc.
NGNE
NASDAQ·Healthcare·Biotechnology·Mkt cap $610.0M
$38.60
▲ +2.63%
P/E
-7.01
Mkt Cap
$610.0M
52-Wk Range
$15.93–$43.66
52-Week Range
$15.93 - $43.66
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 98.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AAV9 gene therapy platform targeting CNS diseases
- Orphan disease focus with regulatory incentives and market exclusivity
- Experienced management team with deep gene therapy expertise
- First-mover advantage in specific rare neurological indications
Bear Case
1 risk
- Above-average volatility (beta 2.0).
Growth
Stable outlook
Clinical trial progression of NGN-401 for Rett syndrome
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+35.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NGNE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 11, 2026
Reported EPS of -$1.53 vs -$1.42 consensus (-7.8% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.8%
Revenue trend · last 8Q
—
—
—
-100%
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 12, 2026
vs Industry
How NGNE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related